Premium
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics
Author(s) -
Carbone Salvatore,
Canada Justin M.,
Billingsley Hayley E.,
Kadariya Dinesh,
Dixon Dave L.,
Trankle Cory R.,
Buckley Leo F.,
Markley Roshanak,
Vo Chau,
Medina de Chazal Horacio,
Christopher Sanah,
Buzzetti Raffaella,
Van Tassell Benjamin W.,
Abbate Antonio
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13309
Subject(s) - cardiorespiratory fitness , empagliflozin , loop (graph theory) , medicine , cardiology , mathematics , endocrinology , diabetes mellitus , type 2 diabetes mellitus , combinatorics
The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO 2 ) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether there was an interaction of the effects of empagliflozin on peak VO 2 of loop diuretics. Empagliflozin reduced body weight (−1.7 kg; P = .031), but did not change peak VO 2 (from 14.5 mL kg −1 min −1 [12.6‐17.8] to 15.8 [12.5‐17.4] mL kg −1 min −1 ; P = .95). However, patients using loop diuretics (N = 9) demonstrated an improvement, whereas those without loop diuretics (N = 6) experienced a decrease in peak VO 2 (+0.9 [0.1‐1.4] vs −0.9 [−2.1 to −0.3] mL kg −1 min −1 ; P = .001), and peak VO 2 changes correlated with the baseline daily dose of diuretics (R = +0.83; P < .001). Empagliflozin did not improve peak VO 2 in patients with T2DM and HFrEF. However, as a result of exploratory analysis, patients concomitantly treated with loop diuretics experienced a significant improvement in peak VO 2 .